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Bacterial keratitis can lead to severe vision loss and corneal scarring, 
and possibly perforation. Early and appropriate management is a key 
factor in decreasing and preventing complication.
Pubmed and Medline were searched for articles related to Pseudo-
monas keratitis between year 2000 and 2017 to get current guidelines 
about the management of Pseudomonas keratitis. These articles are 
reviewed in this article and information related to management is 
summarized. 
The most used agents to treat Pseudomonas are either aminogl-
ycosides (usually gentamicin) fortified with a cephalosporin or mono 
therapy with a fluoroquinolones usually ciprofloxacin. In most areas, 
most strains of Pseudomonas were susceptible to ciprofloxacin. The 
role of topical steroids is discussed, as well as, available options for 
treatment of multidrug resistant Pseudomonas species.
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Introduction 
Bacterial keratitis is a vision threating infection characterized by epithe-
lium loss, stromal infiltration by white blood cells and melting of the 
corneal stoma. It happens when one of the protective mechanisms of 
the ocular surface is sacrificed [1].
Early recognition and administration of appropriate choice of an-
tibiotics is crucial if vision is to be restored. Pseudomonas species is 
commonly associated with contact lens wear [1-5]. Predisposing risk 
factors depend on the geographical locations and can be influenced 
by the penetration of contact lens. Trauma to the eye is an impor-
tant risk factor in developing countries, meanwhile contact lens wear 
remains the main cause in developed countries [6]. A study from Ma-
laysia suggested that Pseudomonas spp. is the main microorganism 
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following vegetation related corneal injury is some 
regions. Pseudomonas group is a common inhabi-
tant of soil, water and vegetation [7].
Other risk factors for bacterial keratitis include 
disease of the ocular surface and previous ocular 
surgeries [8].
Seasonal variation was noted in the presenta-
tion of Pseudomonas spp. keratitis, being mostly 
frequent in summer. Possibly warmer temperature, 
higher humidity and greater exposure to water may 
explain the higher incidence in summer [9].
Biological characterization of 
Pseudomonas species
Pseudomonas species is widespread in the envi-
ronment and it can be isolated from various living 
sources, including plants, animals, and humans [10]. 
The organism is non-fermenting gram-negative, 
non-spore-forming, strictly aerobic, and catalase 
and oxidase positive. It can survive at temperature 
between 4 to 42ºC but not at pH values below 
4-5. Pseudomonas has also the ability to survive on 
minimal nutritional requirements and to tolerate a 
variety of physical conditions which allow it to per-
sist in both community and hospital settings [10]. 
The organism forms biofilms on wet surfaces and in 
hospital environment such as sinks, humidifiers, and 
respiratory therapy equipment [11]. There are nume-
rous Pseudomona s spp. which have been associated 
with opportunistic infections include P. aeruginosa, 
Pseudomonas maltophilia, P. fluorescens, P.putida, 
P. cepacia, P. stutzeri, and P. putrefaciens, but P. 
aeruginosa is the most common reported species 
causing human infection [12].
Virulence of P. aeruginosa 
Pseudomonas aeruginosa is a clinically important 
and opportunistic pathogen, often causing nosoco-
mial infections. P. aeruginosa produces more than 
other species a variety of virulence factors, who-
se expression is regulated by different regulatory 
systems especially by Quorum sensing (QS) system. 
Most clinical isolated strains of P. aeruginosa can 
produce many virulence factors such as elastase, 
alginate, exotoxin A, exotoxin S, exotoxin U, alkali-
ne protease and pyocyanin [13, 14]. P. aeruginosa 
has a single polar flagellum that is responsible for 
motility. It is also involved in the adhesion to respira-
tory epithelial cells. This virulence effect induces an 
inflammatory response by interaction with receptor 
cells. P. aeruginosa synthesizes the exopolysacchari-
de alginate in response to environmental conditions. 
Alginate serves to protect the bacteria as biofilms in 
its surrounding environment and also enhances ad-
hesion to solid surfaces. The organism can produce 
an alginate enzyme under certain infection condi-
tions and both alginate biosynthetic and degrada-
tive enzymes are important for the development, 
maintenance and spread of P. aeruginosa biofilms 
in infected patients [14, 15].
Antimicrobial resistance of P. aeruginosa 
P. aeruginosa is the most common species and it 
colonizes more than 50% of hospitalized patients. 
P. aeruginosa is a leading cause of nosocomial in-
fections, ranking second among the gram-negative 
pathogens reported to the National Nosocomial In-
fection Surveillance System in USA. The organism is 
responsible for severe nosocomial infections such as 
septicemia and pneumonia, life-threatening infec-
tions in immunocompromised persons, and chronic 
infections in cystic fibrosis patients [16]. 
A recent systemic review and meta-analysis study 
indicated that hospitalized patients with Multidrug- 
resistant (MDR) P. aeruginosa infections appear to 
have increased mortality and hospital length [17, 
18]. Infections caused by MDR P. aeruginosa are 
difficult to treat as the majority of isolates exhibit 
varying degrees of innate resistance or the consti-
tutive expression of AmpC β- lactamase and efflux 
pumps, combined with low permeability of the ou-
ter membrane. Acquired resistance is also reported 
due to the production of plasmid mediated AmpC 
beta (β)-lactamase, ESBLs and Metallo β-lactamase 
(MBL) enzymes [18]. Additionally, P. aeruginosa iso-
lates from environment including water, sewage 
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and human feces indicated the presence of high 
resistance rates to commonly used drugs in many 
Arab countries [19-23]. 
 
Epidemiology P. aeruginosa keratitis 
The occurring incidence rate of Pseudomonas aeru-
ginosa keratitis was constant over the last 20 years 
at 1/2500 of daily contact wearers and 1/500 of 
extended wear contact lens [6].
The incidence of Pseudomonas keratitis varies de-
pending on geographical location. Template zones 
have a higher incidence rate of Gram positive bac-
teria causing keratitis and less aggressive disease [6]. 
However, Pseudomonas was found to be the most 
common Gran negative bacterial isolated in Toron-
to, Canada over the past 16 years [24] and in Wes-
tern India with an incidence of 17.14% [1]. In Spain 
an incidence of 12.5% of all bacterial keratitis was 
reported and was found to be the most frequent 
Gram negative microorganisms [8]. In addition, this 
incidence was found to be 12.5% in China [2]. In 
Saudi Arabia, an incidence of 38.4% was reported 
[3].On the other hand, it has been reported that up 
to 80% of all positive cultures in Iran are caused by 
Pseudomonas spp. [4]. Moreover, P. aeruginosa was 
the most frequent bacteria isolated in contact Lens 
related ulcers with an incidence of 75% in France 
[5] and 79.7% in Malaysia [7]. A higher percentage 
of contact lens related cases of Pseudomonas ulcers 
was found in a five year period from 2009 to 2014 
in Texas U.S.A. [25].
Prognosis of bacterial keratitis depends on the 
distance from the limbus and the minimal inhibitory 
concentration (MIC) of the first antibiotic used or 
the lowest MIC if combined treatment is used [6].
The presence of conjunctival chemosis was found 
to be a clinical clue to the Pseudomonas as a cau-
sative agent in bacterial Keratitis [26]. Large ulcers 
are more likely to be caused by Pseudomonas [6].
The stain type of Pseudomonas aeruginosa (in-
vasive or cytotoxic) may affect the clinical presenta-
tion, prognosis and response to antibiotics. It was 
suggested thatpseudomonas keratitis caused by in-
vasive strains had better visual acuity than ones cau-
sed by cytotoxic strains. On the other hand, invasive 
ulcers are less significantly improved compared to 
cytotoxic ones at three months [27].
Risk factors for multiple and extremely drug resis-
tance Pseudomonas include: bandage contact lens, 
topical steroids, previous corneal graft and ocular 
surface disease following Steven Johnson disease 
[28]. 
Management of P. aeruginosa keratitis
As a rule, every case of suspected microbial kera-
titis should be scrapped for culture and sensitivity, 
especially with the increasing number of microbial 
resistant strains. Scrapping should be done with a 
surgical blade such as Bard Parker blade No.15, Ki-
mora spatula or 21 gauge disposable needle. Sam-
ples should be sent immediately to bacteriology 
laboratory. The sample is normally inoculated on 
chocolate agar, blood agar, thioglycolate broth and 
incubated at 37ºC for 24-48 hours. Sabouraud agar 
plates should be also used for detection of yeast 
and rapid growing fungi. These plates should be 
kept at room temperature and 37 ºC for at least 4 
days. Scrapping of small lesions (less than 2 mm2) 
is not advised and is not worthwhile. As a result, 
small lesions should be treated empirically. Scrapes 
should also be sent for preparing a Gram stains [6].
Clinical evaluation to antimicrobial response inclu-
de: blurring of the margins to the infiltrates, decrea-
sed intensity of the infiltrates, decreased stromal 
edema and endothelial plaques, reduced anterior 
chamber reaction, re-epithelialization and cessation 
of corneal melting.
Topical antibiotics are used widely and empirica-
lly. Topical antibiotics remain the best treatment for 
bacterial keratitis. It was found that all frequently 
used antibiotics are equally effective, but the final 
outcome is not satisfactory because of corneal mel-
ting, scaring and perforation [29]. Treatment used 
varies depending on geographical location and 
available local antimicrobial susceptibility of Pseu-
domonas isolates. Monotherapy with ciprofloxacin 
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of 0.3% (or other fluoroquinolones) is commonly 
used. Sub conjunctival injections of gentamicin may 
be also used. The combined use of two fortified 
antibiotics preparation of 1.5% gentamicin and 5% 
cefuroxime covers almost the entire spectrum of 
common causative bacterial pathogens [30]. Ran-
domized clinical trials have demonstrated that mo-
notherapy with fluoroquinolones is not inferior and 
has fewer side effects compared with combination 
treatment [31].
A study from Iran recommended the use of com-
bination of ceftazidime and amikacin or ceftazidime 
and ciprofloxacin as the first treatment based on an-
tibiotic sensitivity of isolated microbes. In that study 
it was shown that Pseudomonas isolates were resis-
tant to chloramphenicol, trimethoprim, vancomycin 
and cefazolin. Moreover, these antibacterial agents 
should not be used as initial therapy in that region 
[32]. For example, In Australia, the major ocular 
pathogens are generally susceptible to the most 
commonly used antibiotics to treat microbial ke-
ratitis, and fluoroquinolones, aminoglycosides and 
cephalosporins is generally reserved for treatment 
of significant microbial keratitis [33].
In China, it was shown that most Gram-negative 
isolates including Pseudomonas was sensitive to 
neomycin but resistant to chloramphenicol [2]. A 
study from Iraq revealed that the use of ciprofloxa-
cin alone as a starting treatment does not cover 
most of the bacteria causing superlative microbial 
keratitis. Another anti-microbial agent should be 
added. The choice of which treatment to be used 
depends on the likely microbial agent, taking into 
consideration the regional risk factors and clinical 
characteristics [30].
In Brazil, Pseudomonas isolates were susceptible 
to ciprofloxacin and ofloxcacin. One out of 239 ca-
ses was found to be resistant to gentamicin. Re-
sistance to fourth generation fluoroquinolones was 
not observed [34]. In a recent study in South India, 
Pseudomonas isolates were found to be the second 
most common resistant bacterial isolate with resis-
tance in bacterial Keratitis after Streptococcus pneu-
monia. The resistance was relatively uncommon and 
did not increase over 12 years (from 2002 to 2013) 
[35]. Data from Iran suggest that Pseudomonas iso-
lates were mostly sensitive to ciprofloxacin followed 
by imipenem, meropenem and ceftazidime [4]. In 
Canada an increasing resistance to erythromycin 
(p=0.018), ceftazidime (P=0.046), piperacillin/tazo-
bactam (P=0.005) was seen in the past 16 years 
[21].
In Spain it is recommended to use aminoglycosi-
des (gentamycin) and fluoroquinolones (ciprofloxa-
cin) and avoid erythromycin due to increasing resis-
tance to it [22].
A recent study evaluated the effect of different 
antibiotics on P. aeruginosa in vitro of primary hu-
man corneal fibroblasts. It was shown that the 
highest activity against planktonic pseudomonas 
was ciprofloxacin, Levofloxacin, and polymyxin B, 
followed by gentamicin and ofloxacin. Cefuroxime 
and chloramphenicol was found to be ineffective. It 
was also found that bactericidal and bacteriostatic 
antibiotics used in bacterial keratitis were unable to 
eradicate Pseudomonas infection of human fibro-
blasts culture in vitro. Their effectiveness depends 
on the cellular location of Pseudomonas [36].
According to the susceptibility of Pseudomonas 
strain the response to topical treatment may be 
affected. Adjuvant treatment with steroids, when 
used with moxifloxacin, was associated with better 
visual outcome in Pseudomonas keratitis caused by 
invasive strains compared to ones caused by cyto-
toxic strains. The size of scar at 3 months in the 
invasive strains was smaller when steroids and moxi-
floxacin were used compared to moxifloxacin alone. 
Less improvement was noted in the cytotoxic group 
(p=0.07) [7, 27].
Most ophthalmologists recommend starting an-
ti-microbial empirically before culture results are 
available [37-39]. A study from Japan showed bet-
ter results when anti-microbial agents were selec-
ted based on culture results, stressing the impor-
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tance of culture results [40]. However, a study from 
Oxford showed that 93.2% of bacteria isolated 
from infected corneas including Gram-positive and 
Gram-negative were sensitive to ciprofloxacin. On 
the other hand, 99.5% were sensitive to the com-
bination of gentamicin and cefuroxime (P=0.0015). 
It was reported that there was no increase in the 
resistance over a decade, as indicated in the study 
period [41].
In some resistant cases, a combination of pipe-
racillin/tazobactam may be useful [27]. The use of 
topical steroids (prednisone phosphate) combined 
with moxifloxacin did not improve the overall clinical 
outcome as showed in a multi-center clinical study 
that enrolled patients from India and USA [42]. 
In general, P. aeruginosa is mostly susceptible to 
fluoroquinolones, but multi drug resistant Pseudo-
monas strains are reported increasing in many cou-
ntry. For example, in Austria, strains are resistant to 
ciprofloxacin, gentamicin, tobramycin and amikacin 
but susceptible to ceftazidime, imipenem, merope-
nem and imipenim. It was also found that P. aeru-
ginosa isolates has shown average susceptibility to 
piperacillin and ticarcillin [42].
Possible synergistic activity is documented bet-
ween anti-microbial against Pseudomonas. Me-
ropenem and ciprofloxacin with 90% of isolates 
showed synergistic or additive effect. This made 
combined anti- microbial a potential treatment aga-
inst multi drug resistant strains [29]. Most common 
prescribed drugs are ciprofloxacin and tobramycin, 
a fortified aminoglycosides. Geographical location 
should be taken in consideration before giving them 
as treatment for P. aeruginosa [30]. 
Multi drug and extreme drug resistant Pseudo-
monas isolates are very difficult to treat. More than 
half of those patients required therapeutic grafts. 
Most sensitivity was reported to imipenem followed 
by colistin and neomycin. Few patients were sensiti-
ve to ceftazidime and azithromycin [25].
In advanced keratitis, continues infusion of to-
pical antibiotics (ceftazidime 50 mg/ ml) with the 
Morgan lens was effective when applied for one 
week followed by conventional topical antibiotics 
[44]. The early use of 19% topical colistin was 
found to be effective in the treatment of multi 
drug resistant Pseudomonas with few side effects 
[42]. Topical colitithemate of 1.6% maybe an effec-
tive topical alternative [43]. Corneal cross-linking is 
a promising new modality for non-healing corneal 
ulcers including ulcers secondary to Pseudomonas 
keratitis [47-48]. Amniotic membrane transplan-
tation is effective for relieving pain, decreasing 
inflammation, stabilizing the cornea and promo-
ting epithelial healing along with topical treatment 
[49]. It was found that double layered amniotic 
membrane transplantation had a good long term 
outcome in Pseudomonas infected corneas with 
descematocele. It reduced the risk of perforation 
and the need for emergent corneal grafting [50]. 
Salicylic acid may be beneficial as an anti-microbial 
agent in the treatment of Pseudomonas aerugi-
nosa. It was shown that salicylic acid alters the 
membrane proteome of Pseudomonas aeruginosa, 
mildly increased the resistance to carbapenem an-
tibiotics only with no effect on other antibiotics. 
Salicylic acid also reduces the clinical score and the 
number of bacteria with no effect on the number 
of neutrophils [51]. 
Conclusion
Pseudomonas, especially P. aeruginosa is mostly re-
lated to contact lens induced microbial keratitis.The 
most common used therapy is mono therapy with a 
fluoroquinolone or fortified aminoglycosides. Most 
strains are still susceptible to these antibiotics but 
geographical location should be taken in considera-
tion. Multidrug resistant Pseudomonas isolates are 
observed in clinical practice and different treatment 
modalities are available.
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